Celecoxib / CA Cancer Research Results

CEL, Celecoxib: Click to Expand ⟱
Features: NSAID
Celecoxib inhibits the formation of prostaglandins: used primarily to treat pain and other symptoms of osteoarthritis, rheumatoid arthritis, joint and musculoskeletal conditions.

Celecoxib is a diaryl-substituted selective cyclooxygenase-2 inhibitor that lowers prostaglandin synthesis and is used clinically as an oral nonsteroidal anti-inflammatory drug. It is formally classified as a small-molecule NSAID and COX-2–preferential inhibitor. Standard abbreviations include celecoxib and CEL. In oncology, its main rationale is suppression of the COX-2/PGE2 inflammatory-tumor axis, with additional COX-2-independent effects reported at higher experimental concentrations, including interference with PDK1/Akt signaling, ER calcium handling, and stress-linked apoptosis pathways. Nestronics lists it as an NSAID and currently indexes mainly EMT, HIF-1α/VEGF, COX-2, NF-κB, p65, and TGF-β/SMAD3-related findings.

Primary mechanisms (ranked):

  1. COX-2 inhibition with reduced PGE2 signaling and downstream inflammatory, proliferative, angiogenic, and immune-evasive tumor support
  2. Suppression of NF-κB-linked inflammatory survival programs
  3. Reduction of hypoxia/angiogenesis signaling including HIF-1α and VEGF in relevant models
  4. Partial inhibition of PDK1/Akt survival signaling in some tumor systems
  5. COX-2-independent ER stress and Ca²⁺ dysregulation via SERCA-related effects at supratherapeutic or high in-vitro concentrations
  6. Contextual chemosensitization, including effects on apoptosis threshold and in some reports drug-resistance programs such as P-gp
  7. Possible ancillary carbonic anhydrase inhibition is mechanistically interesting but not established as the dominant clinical anticancer mechanism

Bioavailability / PK relevance: Celecoxib is orally active. Peak plasma levels occur at about 3 hours, effective half-life is about 11 hours, steady state is reached by about day 5, and the drug is highly protein bound. Exposure is roughly dose-proportional up to 200 mg twice daily, with less-than-proportional increases above that range because of solubility limits. It is metabolized mainly by CYP2C9, so poor metabolizers and strong CYP2C9 interactions are clinically relevant.

In-vitro vs systemic exposure relevance: This is an important translation constraint. Many direct pro-apoptotic, SERCA/ER-stress, and stronger Akt-related anticancer effects are reported in vitro at concentrations commonly above those readily achievable with standard anti-inflammatory dosing. By contrast, COX-2/PGE2 suppression is clearly clinically reachable and is the most exposure-plausible core mechanism. Therefore, low- to mid-micromolar inflammatory and microenvironment effects are more translatable than high-concentration cytotoxic claims.

Clinical evidence status: Strong clinical deployment exists for pain/inflammatory indications, not for cancer treatment. In oncology, evidence is mixed: extensive preclinical support, some small human and adjunct studies, but major randomized adjuvant trials in unselected breast and stage III colon cancer were negative overall. A more recent biomarker-defined signal has emerged in PIK3CA-activated stage III colon cancer, where celecoxib appeared beneficial in subgroup analysis, so any cancer role currently looks biomarker- and context-dependent rather than broadly established.

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 COX-2 / PGE2 inflammatory signaling COX-2 activity ↓; PGE2 tone ↓; proliferation, survival, invasion, immune evasion ↓ Inflammatory prostaglandin signaling ↓ R/G Core anti-inflammatory antitumor mechanism Best-supported and most clinically reachable mechanism; strongest translational anchor for oncology repurposing
2 NF-κB inflammatory survival axis NF-κB/p65 ↓; inflammatory survival transcription ↓ Inflammatory signaling ↓ R/G Reduced survival and inflammatory tone Consistent with Nestronics and broader literature; partly downstream of reduced PGE2 but may also reflect parallel signaling effects
3 HIF-1α / VEGF angiogenesis axis HIF-1α ↓; VEGF ↓; angiogenic support ↓ ↔ or angiogenic signaling ↓ in inflammatory settings G Antiangiogenic pressure Likely relevant in hypoxic and COX-2-high tumors; fits both Nestronics indexing and broader COX-2/PGE2 biology
4 TGF-β / SMAD3 / EMT TGF-β ↓; SMAD3 ↓; EMT ↓; migration/invasion ↓ ↔ G Anti-migratory and anti-invasive effect Nestronics support is specific here; likely more tumor-contextual than universally dominant
5 PDK1 / Akt survival signaling PDK1/Akt ↓ (context-dependent); apoptosis threshold ↓ ↔ R/G COX-independent survival suppression Mechanistically important in the celecoxib literature, but many strong effects are reported at higher in-vitro concentrations
6 Ca²⁺ homeostasis and ER stress ER Ca²⁺ reuptake ↓; cytosolic Ca²⁺ stress ↑; ER stress/apoptosis ↑ Potential stress if exposure is high enough P/R Stress-triggered apoptosis Usually linked to SERCA interference and considered mainly a high-concentration or COX-independent mechanism
7 Mitochondrial apoptosis program Caspase activation ↑; Bcl-2-family survival balance shifts toward apoptosis ↔ R/G Apoptotic execution Generally downstream of Akt inhibition, ER stress, or combined treatment sensitization rather than the first initiating event
8 Chemosensitization Drug sensitivity ↑; apoptosis with cytotoxics ↑ Potential inflammation/pain benefit in host context G Adjunctive therapy potential Observed preclinically and in some clinical adjunct settings, but not confirmed as a broad survival-improving strategy in unselected populations
9 P-gp and resistance signaling P-gp ↓ (model-dependent); intracellular drug retention ↑ ↔ G Possible reversal of drug resistance Interesting but not core; should be treated as secondary and context-specific
10 Carbonic anhydrase inhibition CA-related pH adaptation ↓ (context-dependent) Off-target CA interaction possible ↔ Ancillary microenvironment effect Celecoxib can inhibit carbonic anhydrases, but this is better viewed as a mechanistic side branch than the main oncology rationale for celecoxib itself
11 Clinical Translation Constraint Overall efficacy signal mixed; biomarker-defined benefit more plausible than broad use Cardiovascular, renal, GI, and drug-interaction liabilities constrain chronic escalation G Limits generalized oncology deployment Main constraint is that clinically achievable exposure strongly supports COX-2/PGE2 modulation, whereas many direct cytotoxic claims require higher concentrations; major adjuvant trials were negative overall, though PIK3CA-activated colon cancer is a notable exception signal

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
CA, Carbonic anhydrases: Click to Expand ⟱
Source:
Type:
CA pH Control, Hypoxia Adaptation, and Metastatic Fitness Family of enzymes that catalyze the reversible hydration of carbon dioxide (CO₂) to bicarbonate (HCO₃⁻) and a proton (H⁺).
Carbonic Anhydrase IX (CAIX) is a well-described enzyme in renal cell carcinoma, with its expression being regulated by the hypoxia-inducible factor 1 alpha, it is known for interfering with hypoxia processes.
Carbonic anhydrase 9 (CA9) is a protein to be upregulated under exposure to hypoxic conditions. Hypoxic conditions are known to be associated with resistance to chemotherapy and radiotherapy, and with poor cancer prognosis.
Of the carbonic anhydrases, CA9 and CA12, are transmembrane isozymes that are highly expressed in some tumours, and may be implicated in acidification of the extracellular milieu surrounding cancer cells, thus creating a microenvironment conducive to tumour growth and spread.
Carbonic anhydrase IX, is an endogenous marker for hypoxia.
Scientific Papers found: Click to Expand⟱
5956- CEL,    Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy
- Review, Var, NA
COX2↓, Pain↓, CA↓, PDK1↓, Apoptosis↑,
5958- CEL,    Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition
- in-vitro, Var, NA
COX2↓, CA↓,
5961- CEL,    Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer
- Review, Var, NA
COX2↓, CA↓,
5962- CEL,    The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II
- Study, Var, NA
CA↓,
5964- CEL,    Celecoxib pathways: pharmacokinetics and pharmacodynamics
- Review, Var, NA
COX2↓, *Pain↓, *Inflam↓, Apoptosis↑, TumCCA↑, angioG↓, ER Stress↑, VEGF↓, MMP9↓, PDK1↓, Akt↓, CA↓, CardioT↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

PDK1↓, 2,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 2,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Migration ⓘ

CA↓, 5,   MMP9↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,  

Functional Outcomes ⓘ

CardioT↑, 1,   Pain↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Functional Outcomes ⓘ

Pain↓, 1,  
Total Targets: 2

Scientific Paper Hit Count for: CA, Carbonic anhydrases
5 Celecoxib
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:4  Target#:37  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page